Juniper Pharmaceuticals Inc (JNP):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C10054)
◆英語タイトル:Juniper Pharmaceuticals Inc (JNP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10054
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:45
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Juniper Pharmaceuticals Inc (Juniper), formerly Columbia Laboratories Inc is a women’s health therapeutic company that focuses on developing therapeutics that address unmet medical needs. It develops, manufactures, licenses and sells pharmaceutical products in women’s health. The company utilizes proprietary drug delivery technologies to treat various medical conditions to commercial partners. Its proprietary technology includes intravaginal ring (IVR) and bioadhesive gel (BDS). Juniper provides a range of drug development services and consulting services to the pharmaceutical industry. The company operates in pharmaceutical industry and also provides in-house expertise for internal pharmaceutical programs. The company operates in the US, the UK, Switzerland and other countries. Juniper is headquartered in Boston, Massachusetts, the US.

Juniper Pharmaceuticals Inc (JNP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Juniper Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Juniper Pharma Acquires Three New Products to its Proprietary Pipeline 12
Partnerships 13
Juniper Pharma Services Enters into Agreement with Crystec Pharma 13
Molecular Profiles Enters Into Co-Development Agreement With Telormedix 14
Molecular Profiles Enters Into Agreement With Onyx Scientific 15
Licensing Agreements 16
Dare Bioscience Enters into Licensing Agreement with Juniper Pharma 16
Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 18
Columbia Labs Enters into Licensing Agreement for IVR Technology 20
Asset Transactions 21
Lil’ Drug Store Exercises Option to Acquire Rights for Legatrin PM from Columbia Labs for USD2.2 Million 21
Acquisition 22
Catalent Acquires Juniper Pharma 22
Columbia Labs Acquires Molecular Profiles For US$25 Million 24
Juniper Pharmaceuticals Inc – Key Competitors 25
Juniper Pharmaceuticals Inc – Key Employees 26
Juniper Pharmaceuticals Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Strategy And Business Planning 28
Sep 18, 2017: Juniper Pharmaceuticals Announces Strategic Reprioritization 28
Financial Announcements 30
Aug 09, 2018: Juniper Pharmaceuticals reports second quarter 2018 financial and operating results 30
May 10, 2018: Juniper Pharmaceuticals Reports First Quarter 2018 Financial and Operating Results 31
Mar 08, 2018: Juniper Pharmaceuticals Reports Full-Year 2017 Financial and Operating Results 32
Nov 02, 2017: Juniper Pharmaceuticals Reports Third Quarter 2017 Financial and Operating Results 34
Aug 03, 2017: Juniper Pharmaceuticals Reports Second Quarter 2017 Financial and Operating Results 35
May 04, 2017: Juniper Pharmaceuticals Reports First Quarter 2017 Financial and Operating Results 36
Mar 07, 2017: Juniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results 38
Corporate Communications 40
Mar 21, 2018: Juniper Pharmaceuticals Appoints Richard Messina to Board of Directors 40
Sep 11, 2017: Juniper Pharmaceuticals Appoints Jennifer Good to Board of Directors 41
Other Significant Developments 42
Jan 31, 2018: Juniper Pharmaceuticals to Explore Strategic Alternatives 42
Jan 02, 2018: Juniper Pharma Outlines Strategic Priorities for 2018 and Reports Recent Portfolio Progress 43
Aug 08, 2017: Major Progress in Next Generation Medicines Initiative 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Juniper Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Juniper Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Juniper Pharma Acquires Three New Products to its Proprietary Pipeline 12
Juniper Pharma Services Enters into Agreement with Crystec Pharma 13
Molecular Profiles Enters Into Co-Development Agreement With Telormedix 14
Molecular Profiles Enters Into Agreement With Onyx Scientific 15
Dare Bioscience Enters into Licensing Agreement with Juniper Pharma 16
Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 18
Columbia Labs Enters into Licensing Agreement for IVR Technology 20
Lil’ Drug Store Exercises Option to Acquire Rights for Legatrin PM from Columbia Labs for USD2.2 Million 21
Catalent Acquires Juniper Pharma 22
Columbia Labs Acquires Molecular Profiles For US$25 Million 24
Juniper Pharmaceuticals Inc, Key Competitors 25
Juniper Pharmaceuticals Inc, Key Employees 26
Juniper Pharmaceuticals Inc, Subsidiaries 27

List of Figures
Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Juniper Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Juniper Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Juniper Pharmaceuticals Inc (JNP):製薬・医療:M&Aディール及び事業提携情報(Juniper Pharmaceuticals Inc (JNP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆